emrosi journey medical news

FDA approves Journey Medical’s rosacea treatment Emrosi

The US’ Food and Drug Administration (FDA) has approved Journey Medical’s Emrosi, the brand name for its 40mg minocycline hydrochloride extended-release capsules, to be used in the treatment of dermatological condition rosacea.

Reuters on MSN · 1d

US FDA approves Journey Medical's drug for long-term skin condition

The U.S. Food and Drug Administration has approved Journey Medical's drug for the treatment of a long-term skin condition called rosacea, the company said on Monday.

Business Insider · 1d

Journey Medical announces U.S. FDA approval of Emrosi

Journey Medical (DERM) announced that the FDA has approved Emrosi, formerly referred to as DFD-29, for the treatment of inflammatory lesions of

Seeking Alpha · 1d

Journey gets FDA okay for Emrosi, releases preliminary Q3 earnings report

Journey Medical (DERM) received FDA approval for its drug Emrosi for the treatment of rosacea and released its preliminary Q3 earnings report. Read more here.

1don MSN

What's Going On With Journey Medical Stock Today?

Journey Medical (NASDAQ:DERM) shares are trading higher Monday after the company announced the U.S. Food and Drug ...

Yahoo Finance12d

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

SCOTTSDALE, Ariz., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results